Sort
82,697 grants matching “vaccine development”
Coordinating Research on Emerging Arboviral Threats Encoing the Neotropics (CREATE-NEO)
$1,548,235Nikos Vasilakis · University Of Texas Med Br Galveston · U01 · FY2024 · AI
Modeling Early Immunity to Human Influenza Infection
$1,548,032Stuart C. Sealfon · Icahn School Of Medicine At Mount Sinai · U19 · FY2016 · AI
The Military HIV Research Program (MHRP) Clinical Trial Unit
$1,547,861Merlin L Robb · Henry M. Jackson Fdn For The Adv Mil/Med · UM1 · FY2024 · AI
Immune development in early life (IDEAL) shapes vaccine response, respiratory infectious diseaseand asthma
$1,546,537Ofer Levy · Boston Children'S Hospital · U19 · FY2023 · AI
Development of Adjuvant with Vaccines for Tuberculosis and Shigellosis
$1,546,239Kathlenn Kozar · Tulane University · N01 · FY2017 · AI
American and Asian Centers for Arboviral Research and Enhanced Surveillance (A2CARES)
$1,546,211Eva Harris · University Of California Berkeley · U01 · FY2023 · AI
HPV Serology
$1,545,867Leonard Freedman · Leidos Biomedical Research, Inc. · N01 · FY2022 · CA
IL-2:IL-15 cytokine receptor: implications for cancer therapy and vaccine
$1,545,717Thomas Waldmann · Division Of Clinical Sciences - Nci · ZIA · FY2018 · CA
CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS)
$1,545,308Richard Webby · St. Jude Children'S Research Hospital · N01 · FY2016 · AI
University of Rochester Center for AIDS Research
$1,544,856Stephen Dewhurst · University Of Rochester · P30 · FY2017 · AI
Coordinating Research on Emerging Arboviral Threats Encoing the Neotropics (CREATE-NEO)
$1,544,479Nikos Vasilakis · University Of Texas Med Br Galveston · U01 · FY2023 · AI
Sources, Transport, Exposure & Effects of PFAS (STEEP) Center - RENEWAL
$1,544,314Rainer Lohmann · University Of Rhode Island · P42 · FY2024 · ES
Clinical Trials of Vaccines for Respiratory Syncytial Virus and Related Viruses
$1,544,121Peter Leon Collins · National Institute Of Allergy And Infectious Diseases · ZIA · FY2019 · AI
Natural History of HPV Infection to Neoplasia
$1,543,996Anna-Barbara None Moscicki · University Of California, San Francisco · R37 · FY2007 · CA
Host Defense Against HIV-related Pulmonary Infections
$1,543,865Louisiana State Univ Hsc New Orleans · P01 · FY2004 · HL
United States Military HIV Research Program (MHRP) Clinical Trials Unit
$1,543,614Robert A. Gramzinski · Walter Reed Army Institute Of Research · UM1 · FY2018 · AI
Immune Response Consortium: Integrated In Silico, In Vitro, and In Vivo Studies
$1,543,423Arup K. Chakraborty · Massachusetts Institute Of Technology · P01 · FY2008 · AI
Vanderbilt Vaccine and Treatment Evaluation Unit
$1,543,286Clarence Buddy Creech · Vanderbilt University Medical Center · UM1 · FY2022 · AI
Adoptive Cell Transfer Immunotherapy of Cancer
$1,543,070Steven Rosenberg · Division Of Basic Sciences - Nci · ZIA · FY2010 · CA
Immune development in early life (IDEAL) shapes vaccine response, respiratory infectious diseaseand asthma
$1,542,768Ofer Levy · Boston Children'S Hospital · U19 · FY2024 · AI
Early in vivo Expressed Antigens and their Role in Virulence, Immune Response, and Vaccines for Coccidioidomycosis
$1,542,693Paul Stephen Keim · Northern Arizona University · U19 · FY2023 · AI
Poxvirus Modulation of Immune Responses
$1,542,638Janice S Blum · Indiana University Indianapolis · P01 · FY2009 · AI
Immune correlates of protection
$1,542,573Richard A Koup · National Institute Of Allergy And Infectious Diseases · ZIA · FY2020 · AI
Influenza vaccination using a microneedle patch
$1,542,519Mark R Prausnitz · Georgia Institute Of Technology · U01 · FY2010 · EB
Adjuvant development within the context of a vaccine to protect against B. pertussis
$1,542,270Tulane University Of Louisiana · N01 · FY2018 · AI